Pdl Biopharma Stock Current Valuation
Valuation analysis of PDL BioPharma helps investors to measure PDL BioPharma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
PDL BioPharma Company Current Valuation Analysis
PDL BioPharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current PDL BioPharma Current Valuation | 213.07 M |
Most of PDL BioPharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, PDL BioPharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, PDL BioPharma has a Current Valuation of 213.07 M. This is 98.52% lower than that of the Healthcare sector and 95.41% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 98.72% higher than that of the company.
PDL Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PDL BioPharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of PDL BioPharma could also be used in its relative valuation, which is a method of valuing PDL BioPharma by comparing valuation metrics of similar companies.PDL BioPharma is currently under evaluation in current valuation category among related companies.
PDL Fundamentals
| Return On Equity | -7.36 | |||
| Return On Asset | -4.1 | |||
| Operating Margin | (166.77) % | |||
| Current Valuation | 213.07 M | |||
| Shares Outstanding | 114.23 M | |||
| Shares Owned By Insiders | 2.27 % | |||
| Shares Owned By Institutions | 96.53 % | |||
| Number Of Shares Shorted | 11.87 M | |||
| Price To Earning | 526.67 X | |||
| Price To Book | 0.73 X | |||
| Price To Sales | 11.03 X | |||
| Revenue | 27.76 M | |||
| Gross Profit | 13.43 M | |||
| EBITDA | (42.98 M) | |||
| Net Income | (39.18 M) | |||
| Cash And Equivalents | 105.45 M | |||
| Cash Per Share | 0.93 X | |||
| Total Debt | 13.51 M | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 13.68 X | |||
| Book Value Per Share | 3.69 X | |||
| Cash Flow From Operations | (56.35 M) | |||
| Short Ratio | 5.20 X | |||
| Earnings Per Share | (1.32) X | |||
| Price To Earnings To Growth | (0.35) X | |||
| Number Of Employees | 109 | |||
| Beta | 1.14 | |||
| Market Capitalization | 282.14 M | |||
| Total Asset | 1.01 B | |||
| Retained Earnings | 594.7 M | |||
| Working Capital | 245.97 M | |||
| Current Asset | 282.71 M | |||
| Current Liabilities | 36.74 M | |||
| Z Score | 12.0 | |||
| Five Year Return | 8.94 % | |||
| Last Dividend Paid | 0.05 |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards PDL BioPharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, PDL BioPharma's short interest history, or implied volatility extrapolated from PDL BioPharma options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as PDL BioPharma using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in PDL Stock
If you are still planning to invest in PDL BioPharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PDL BioPharma's history and understand the potential risks before investing.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |